论文部分内容阅读
目的观察我国治疗用卡介苗(CT-BCG)预防浅表性膀胱癌术后复发情况及其不良反应。方法对117例浅表性膀胱癌患者术后给予CT-BCG治疗,另对53例患者采用丝裂霉素C(MI-C)治疗,作为对照。CT-BCG组每次用药120mg,MI-C组40mg。用导管灌注膀胱,2h后自行排出。术后2或3周开始,不同时间用药1次,直至1年。观察两组的复发情况及不良反应发生率。结果CT-BCG组复发率为18.8%,MI-C组为13.2%,二者差异无统计学意义;不良反应主要为膀胱炎症状(尿痛、尿频、血尿等)及低热,MI-C组无低热患者,且膀胱炎症状也较CT-BCG组轻。结论CT-BCG预防浅表性膀胱癌术后复发药效良好,无严重不良反应发生。
Objective To observe the postoperative recurrence of superficial bladder cancer and its adverse reactions after treatment of BCG (CT-BCG) in our country. Methods A total of 117 patients with superficial bladder cancer were treated with CT-BCG. Another 53 patients were treated with mitomycin C (MI-C) as a control. Each dose of CT-BCG group 120mg, MI-C group 40mg. Perfusion catheter with catheter, 2h after discharge. 2 or 3 weeks after the start of medication at different times 1 time until 1 year. The recurrence and the incidence of adverse reactions in both groups were observed. Results The recurrence rate was 18.8% in CT-BCG group and 13.2% in MI-C group. There was no significant difference between the two groups. The main adverse reactions were cystitis symptoms (dysuria, urinary frequency, hematuria, etc.) and MI-C No fever patients, and cystitis symptoms than CT-BCG group lighter. Conclusion CT-BCG can prevent recurrence of superficial bladder cancer with good efficacy and no serious adverse reactions.